|
Low
Frequency of Renal Function Impairment during One-year of Therapy
with Tenofovir-containing Regimens in a Real-world Setting
Concern exists about the risk of nephrotoxicity
using tenofovir/TDF (Viread)
in HIV-infected patients.
To
evaluate this risk, researchers in Spain performed a retrospective
case-control study including 122 consecutive TDF-naive patients
who started treatment with TDF-containing regimens and 194 patients
receiving antiretroviral therapy with other antiretroviral drugs.
Results
· During
a 12-month observation period 5 (4.1%) patients in the TDF group
versus 1 (0.5%) in the control group developed grade 1 or higher
serum creatinine elevations
(p
= 0.018).
· Only
2 (1.6%) patients discontinued TDF treatment as a result of serum
creatinine level elevations.
· In
4 of the 5 patients developing creatinine elevations TDF was combined
with lopinavir-ritonavir
(Kaletra).
The
authors conclude, “The use of TDF in clinical practice during a
12-month period is associated with low risk of mild renal failure.
Further studies to assess long-term renal safety of this drug are
needed.”
Infectious Diseases Unit, Internal Medicine Department,
Hospital General Universitario de Elche, Alicante, Spain.
08/08/05
Reference
S
Padilla and others. Low frequency of renal function impairment during
one-year of therapy with tenofovir-containing regimens in the real-world:
a case-control study. AIDS Patient Care and STDS 19(7): 421-424.
July 2005.
|
Link
to FDA-approved Anti-HIV Drugs
|
|
|
|
|
|
